The US Food and Drug Administration (FDA) has approved Ojjaara (momelotinib) for the treatment of intermediate or high-risk myelofibrosis.
In September 2024, the FDA approved momelotinib for patients with intermediate- or high-risk myelofibrosis, including primary and secondary
Sierra Oncology noted in a company-issued press release that if momelotinib is approved by the FDA that they anticipate making the drug
Momelotinib has emerged as a new FDA-approved treatment option for patients with myelofibrosis and anemia.
The FDA approval of momelotinib is supported by data from the crucial MOMENTUM study, along with a subpopulation of adult sufferers with
FDA approves Ojjaara (momelotinib) Ojjaara (momelotinib) approved in the US as the first and only treatment indicated for myelofibrosis
cancer treatment. FDA Approves Momelotinib (Ojjaara) for Myelofibrosis Patients With AnemiaPublished on Septem. fda approval.
The US Food and Drug Administration (FDA) has approved Ojjaara (momelotinib) for the treatment of intermediate or high-risk myelofibrosis.
26. FDA Approves Momelotinib for Myelofibrosis With Anemia (2024). Available online at: Google
Comments
What the hell would the FDA have to do with it? This is a piece of machinery. They would have NO say about it whatsoever.